Skip to main content

Aztreonam Pregnancy and Breastfeeding Warnings

Brand names: Azactam, Cayston

Medically reviewed by Drugs.com. Last updated on Aug 8, 2023.

Aztreonam Pregnancy Warnings

Aztreonam has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal evidence of embryotoxicity, fetotoxicity, or teratogenicity. There are no controlled data from human pregnancy studies. Aztreonam crosses the placenta and enters the fetal circulation. Aztreonam should only be given during pregnancy when need has been clearly established.

See references

Aztreonam Breastfeeding Warnings

Aztreonam is excreted into human milk in small amounts that are less than 1% of maternal serum concentrations. Systemic effects in the infant are considered unlikely. Aztreonam is considered compatible with breast-feeding by the American Academy of Pediatrics.

See references

See also

References for pregnancy information

  1. Product Information. Azactam (aztreonam). Bristol-Myers Squibb. 2002;PROD.
  2. Product Information. Cayston (aztreonam). Gilead Sciences. 2010.

References for breastfeeding information

  1. Fleiss PM, Richwald GA, Gordon J, et al. Aztreonam in human serum and breast milk. Br J Clin Pharmacol. 1985;19:509-11.
  2. Product Information. Azactam (aztreonam). Bristol-Myers Squibb. 2002;PROD.
  3. Committee on Drugs, 1992 to 1993. The transfer of drugs and other chemicals into human milk. Pediatrics. 1994;93:137-50.
  4. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. Baltimore, MD: Williams & Wilkins. 1998.
  5. Product Information. Cayston (aztreonam). Gilead Sciences. 2010.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer